Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of more than 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" in the subject line.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2021a 2022e 2023e 2024e  2025e  2026e  2027e Peak Sales NPV*
Product Portfolio                  
Cimzia 1,841 2,021 2,052 1,966 1,730 1,414 1,129   4,625
Vimpat 1,549 1,043 595 487 421 375 348   1,631
Keppra  970 719 631 576 539 503 484   2,107
Briviact 355 461 542 605 669 590 389 657 1,746
Neupro 307 287 261 230 212 198 183   795
Evenity**   774 956 1,100 1,220 1,275 1,280 1,696   
Nayzilam 57 83 111 137 156 165 159 201 476
Bimzelx 4 49 230 591 984 1,371 1,718 3,017 5,968
Fintepla   111 244 361 482 577 615 803 1,970
Potential new Products
(global sales, non-risk adj.)
                 
Zilucoplan   0 43 160 289 434 581 983 1,916
Rozanolixizumab    0 27 105 210 333 426 917 1,629
Dapimab   0 0 4 36 125 144    
Staccato alprazolam   0 2 15 47 87 133 331 498 
Bepranemab   0 0 11 43 64 45    

*If cell blank: not sufficient data available
**global sales 

UCB FY Consensus Earnings Estimates (Average)

In € million 2021a 2022e 2023e 2024e  2025e 2026e
Net Sales 5,471   5,059  5,091  5,627 6,165 6,480
Revenue 5,777   5,377 5,370 5,906  6,445 6,771
Adjusted EBIT 1,318  744 798 1,154 1,539  1,680
Adjusted EBITDA 1,641   1,160 1,270 1,647  2,026 2,193
Net Profit*  1,058  520 593  902 1,236  1,361
Core EPS (€) 6.49  3.96 4.32 6.08 7.85 8.50 

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2021a 2022e 2023e 2024e  2025e  2026e  2027e Peak Sales NPV
Product Portfolio                  
Cimzia 1,841 2,043 2,063 1,962 1,670 1,385 1,123   4,564
Vimpat 1,549 1,046 594 505 449 405 378   1,627
Keppra  970 717 633 578 534 497 473   1,867
Briviact 355 469 543 608 665 605 355 651 1,736
Neupro 307 295 267 230 201 194 178   673
Evenity**   762 966 1,116 1,242 1,245 1,324 1,426   
Nayzilam 57 81 113 136 156 160 168 180 500
Bimzelx 4 46 237 590 938 1,280 1,716 2,850 5,376
Fintepla   112 239 372 498 600 634 800 1,694
Potential new Products**
(global sales, non-risk adj.)
                 
Zilucoplan   0 52 176 304 423 633 1,000 1,995
Rozanolixizumab    0 26 93 189 300 412 1,000 1,300
Dapimab   0 0 0 50 100 112    
Staccato alprazolam   0 0 9 30 60 113 255 529 
Bepranemab   0 0 0 27 27 40    

*If cell blank: not sufficient data available
**global sales   

UCB FY Consensus Earnings Estimates (Median)

In € million 2021a 2022e 2023e 2024e  2025e 2026e
Net Sales 5,471   5,061  5,160  5,672 6,166  6,558
Revenue 5,777   5,394 5,387 5,920 6,426  6,792
Adjusted EBIT 1,318   740 892 1,232 1,692   1,737
Adjusted EBITDA 1,641   1,169 1,268  1,661 2,082 2,221
Net Profit*  1.058  516 663  972 1,327 1,405
Core EPS (€) 6.49  3.96 4.28 6.17 8.19  9.27 

*attributable to UCB shareholders

Downloads:
UCB FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated 16 Sept 2022



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.